SCYNEXIS Announces Pricing of Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., April 22, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of 4,675,324 shares of its common stock at a public offering price of $7.70 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by SCYNEXIS. In addition, SCYNEXIS has granted the underwriters a 30-day option to purchase up to an additional 701,298 shares of common stock at the public offering price less the underwriting discounts and commissions to cover over-allotments, if any.

RBC Capital Markets and Canaccord Genuity are acting as joint book-running managers on the transaction. In addition, JMP Securities is acting as lead manager and Needham & Company is participating as co-manager in the offering.

A registration statement relating to the securities being sold in this offering has been filed with the U.S. Securities and Exchange Commission and was declared effective on April 22, 2015. This offering is being made only by means of a written prospectus forming part of the effective registration statement. Copies of the final prospectus, when available, may be obtained on the SEC EDGAR Filings Website:, or from RBC Capital Markets, Attention: Prospectus Department, Brookfield Place, 200 Vesey Street 8th Floor, New York, NY 10281, telephone (877) 822-4089 or Canaccord Genuity Inc., Attn: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110, telephone (617) 371-3900, or by email at

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit

         Chuck Osborne
         Chief Financial Officer
         Tel: 919.544.5600

         Media Relations
         Heather Savelle
         MacDougall Biomedical Communications
         Tel: 781.235.3060

         Investor Relations
         Jillian Connell
         The Trout Group LLC
         Tel: 646.378.2956
Source: SCYNEXIS, Inc.